Introduction
Parkinson disease (PD [MIM 168600]) is characterized clinically by asymmetric resting tremor, bradykinesia, muscle rigidity, and postural instability. 1 
Dopaminergic loss and
Lewy bodies in surviving neurons of the substantia nigra support a pathologic diagnosis. 2 Although considered a sporadic illness, 10%-30% of individuals with PD report a first-degree relative with parkinsonism. 3 Linkage and se- 4, 5 Although familial parkinsonism attributed to mutant genes is uncommon, the molecular etiology discovered might be generalizable to idiopathic PD. For instance, antibodies to a-synuclein robustly stain
Lewy bodies and neuritic pathology, 6 whereas mutations in Parkin and PINK1 have emphasized the role of stressinduced mitochondrial dysfunction in PD. 7 We have performed genome-wide linkage analysis of a multi-incident northern French family (P30; Figure 1A) with autosomal-dominant late-onset parkinsonism for which known genetic causes of parkinsonism were excluded (unpublished data). 8 Linkage analysis identified two regions with suggestive two-point LOD scores > 2 (q ¼ 0), a 31 cM interval between D3S1763 and D3S1580, To protect confidentiality, the pedigrees do not show some individuals and siblings and/or gender is sometimes disguised with a diamond. All samples genotyped are indicted as heterozygous mutations (M) or as wild-type (wt). The asterisk (*) indicate that this individual did not fulfill the criteria for PD, but presented resting tremor and akinesia.
and a 15 cM interval between D5S2055 and D5S393. After saturation of both loci with short tandem repeat (STR) markers, significant linkage was obtained only for chromosomal region 3q26-q28. Genomic analysis subsequently led to the identification of eukaryotic translation initiation factor 4-gamma 1 (EIF4G1) mutations (protein eIF4G1 [MIM 600495] ) in affected subjects with familial parkinsonism and idiopathic Lewy body disease. eIF4G1 is a component of the translation initiation complex, eIF4F. 9, 10 We demonstrate that the two most frequent mutations impair complex formation, consistent with a dominant-negative loss of function, and are associated with mitochondrial dysfunction when cells are stressed.
Subjects and Methods

Subjects Ascertainment
The institutional review boards of all participating institutions approved the protocol (institutional review boards France CPP 94/07), and informed consent was obtained from all affected and control subjects. Participating individuals were examined by neurologists specializing in movement disorders. A full history, including a family history and a neurological examination, was completed for each patient. A clinical diagnosis of PD was determined by the presence of at least two of three cardinal signs (resting tremor, bradykinesia, and rigidity), improvement through adequate dopaminergic therapy (when tried), and the absence of atypical features or other causes of parkinsonism. Clinical criteria for probable and possible PD were consistent with former classifications. 1,2 Familial history is defined herein as one or more affected relatives within two degrees of relationship.
Linkage Analysis
Peripheral blood samples were collected and genomic DNA was extracted with standard techniques. Tri-and tetra-nucleotide repeat genome-wide genotyping was completed by the mammalian genotyping service of Marshfield in family P30, for 403 markers at approximately 10 cM resolution. Linkage analysis employed MLINK with a dominant model for two-point LOD scores and SIMWALK2 for nonparametric statistics and haplotype analysis. 11, 12 The frequency of the deleterious allele was set at 0.0001; marker-allele frequencies were from CEPH or determined empirically. The map positions for each marker were taken from Marshfield and Rutgers combined linkage physical map. 13 For tightly linked loci with no observed recombinants the intermarker genetic distances were assigned as 0.01 cM.
Sequencing Analysis and Mutation Screening
Gene sequencing of all coding exons in the 3q26-q28 interval was performed for the three affected members of family P30 (individuals with symptom onset of 61, 62, and 56 years [ Figure 1A , III-2, III-3, III-5]) with an ABI 3730 sequencer with SeqScape v2.5 analysis software (Applied Biosystems). Electrophoregrams were compared with CEPH 1331-01 and -02 control subjects obtained from Genethon and the human reference sequence from the UCSC database. Primers designed for amplification of all exons including exon-intron junctions of EIF4G1 are provided in Table  S1 , available online. Mutations segregating with the disease were further assessed in the other P30 members (n ¼ 23), in control subjects of the northern French (n ¼ 146), and in other subjects of European descent (n ¼ 370 (Table S2) . Eighteen of these STR markers are novel (prefixed with Chr3_ as ''D segment'' numbers are no longer available) and were designed by searching for repeat polymorphisms in 6.77 Mb of genomic sequence spanning the locus. One primer of each pair was labeled with a fluorescent tag; amplified sequences are available on Table S1 . PCR reactions were performed under standard conditions and products were run on an ABI 3730 genetic analyzer. Results were analyzed with GeneMapper 4.0 software (Applied Biosystems). Five SNPs located in EIF4G1, rs4912537, rs2178403, rs2293605, rs1879244 and rs2230571, were included. Marker-allele frequencies for the European population were obtained from the CEPH genotype database, the Human HapMap database, or estimated by genotyping 100 unrelated healthy subjects from North America of European descent. NCBI build 36.1 is referenced throughout.
Testing for EIF4G1 Copy-Number Variation
To determine whole-gene copy number, primer pairs, and probes were designed against exon 10, 18, and 24 of EIF4G1. An endogenous control assay was designed against exon 5 of the presenilin 2 gene. All primers and probes were purchased from Applied Biosystems and sequences are available on Table S1 . Quantitative PCR was carried out with TaqMan expression chemistry protocol; 25 ng genomic DNA was amplified with 0.25 ml primer probe and 2.5 ml TaqMan 2X Universal PCR Master Mix (Applied Biosystems). The thermal cycle conditions were performed at 50 C for 2 min and at 95 C for 10 min, followed by 40 cycles at 95 C for 15 s for denaturation and at 60 C for 1 min for annealing and extension. All assays were performed in triplicate on the ABI 7900HT Fast Real-Time PCR System and analyzed with ABI SDS 2.2.2 Software (Applied Biosystems).
EIF4G1 Cloning and Coimmunoprecipitation Studies of Protein-Complex Binding Partners
Full-length EIF4G1 wild-type (WT) and a dominant negative mutant were amplified from plasmids as previously described 14 and subcloned into pcDNA6.2-V5 and pcDNA6.2/C-EmGFP-Dest expression vectors. The eIF4G1 p.Ala502Val and p.Arg1205His mutations were subsequently introduced with site-specific mutagenesis (primers available in Table S1 ). HEK293T cells, maintained in Opti-mem 1þGlutaMAX1 with 10% of fetal calf serum and penicillin/streptomycin (all GIBCO) at 37 C and 5% CO2, were transfected with cDNA encoding the respective WT or mutant eIF4G1-V5 proteins with Lipofectamine 2000 according to the manufacturer's instructions (Invitrogen). Cells were harvested 48 hr after transfection and lysed in 50 mM Tris/HCL, 150 mM NaCl, and 0.1% Triton X-100. To avoid unspecific binding during immunoprecipitation, we precleared crude lysates by rotating them at 4 C for 1 hr with Protein A/G ultralink resin (Thermo Scientific) followed by centrifugation at 13,000 3 g for 10 min. After performing a BCA Protein assay (Pierce), equal amounts of supernatant were combined with protein G Dyna beads (Invitrogen) preconjugated with monoclonal mouse anti-V5 antibodies (Invitrogen) and rotated on a spinning wheel for 4 hr at 4 C.
The resulting immunocomplex was stringently washed with intraperitoneal (IP) buffer/PBS and eluted in SDS-Sample buffer (Invitrogen). Immunoprecipitated and coprecipitated proteins were analyzed with SDS PAGE/immunoblot technologies. For protein detection, monoclonal anti-V5 (Invitrogen) and polyclonal rabbit eIF4E, eIF3e, and eIF4A (Abcam) were applied. ImageJ was used to quantify the relative amounts of copurified interactors eIF4A1, eIF4E, and eIF3e, taking into account the amounts in the full lysates and the amount of immunoprecipitated eIF4G1 proteins. One-way ANOVA was applied for statistical analysis.
Assessment of Mitochondrial Function by Flow Cytometry
HEK293T cells were transfected with plasmids encoding GFP-tagged eIF4G1 proteins (WT, p.Ala502Val, and p.Arg1205His) and subsequently subjected to viability studies with fluorescence activated cell sorting (FACS) analysis. Incorporation of the mitochondrial-permeable dye tetramethyl rhodamine ethyl ester (TMRE; Invitrogen) has been shown to reflect mitochondrial activity and was used as an indicator for cellular viability. Cells, maintained at 37 C in Opti-mem 1þGlutaMAX1 with 10% fetal calf serum medium (both GIBCO), were seeded at a density of 150,000 cells/6-well and transfected 24 hr prior to FACS analysis. Duplicates of each condition were treated with either 0 or 0.5 mM H 2 O 2 for 6 hr. Labeling with 100 nM TMRE was performed by directly adding TMRE from a DMSO stock solution (0.2 mM) to the growth medium and incubating for 30 min at 37 C. After two washing steps with warm PBS containing 1% FBS, cells were trypsinized, resuspended, and immediately subjected to FACS analysis. We established specific settings for the separation into transfected (GFP positive) and untransfected (GFP negative) as well as viable (TMRE positive) and TMRE negative cells by using appropriate controls including (1) untransfected, no TMRE; (2) transfected, no TMRE; (3) untransfected, TMRE stained; and (4) transfected, TMRE stained samples. For each sample, 100,000 events were acquired and subsequently analyzed. After removal of background counts and the exclusion of untransfected (GFP negative) cells, average TMRE loading values were based on at least 25,000 cells. The number of TMRE positive cells were calculated as the percentage of the total number of GFP positive cells in the respective sample.
Results
Genetic and Physical Mapping
Genome-wide analysis of the P30 pedigree led us to identify two regions with suggestive two-point LOD scores > 2 (q ¼ 0), a 31 cM interval between D3S1763 and D3S1580, and a 15 cM interval between D5S2055 and D5S393. The two loci on chromosomes 3 and 5 were saturated with STRs at <2.0 cM resolution to maximize genetic information, and genotype segregation with disease was reanalyzed with additional DNA samples from family P30. Significant linkage was obtained only for chromosomal region 3q26-q28 (mLOD ¼ 3.01) with a haplotype shared by all affected relatives.
Identification of an EIF4G1 Mutation in Family P30
In silico analysis revealed that the critical interval contained 159 genes (1432 exons). We sequenced each of these along with their donor and acceptor splice sites by using genomic DNA samples from three affected first cousins of P30 ( Figure 1A ; III-2, III-3, III-5). We found 236 known SNPs and 33 novel variants with only five that were present in all three affected family members sequenced; three intronic variants were located more than 20 bases from exon-intron boundaries. Of those novel variants, only EIF4G1 mutation c.3614G>A (p.Arg1205His) was found to segregate with disease in all ten blood-related, affected family members (family P30 two-point LOD ¼ 3.55, q ¼ 0). The mutation was absent in 146 unrelated control subjects from the same ethnical and geographical origin and in 370 unrelated North American control subjects of European descent. Because chromosome 3q26-q28 is a fragile site in cancer and genomic multiplications are associated with malignancy, 10 probes in EIF4G1 were used to grossly assess copy number variants but none were found (n ¼ 225 affected subjects). eIF4G1 c.3614G>A is located in exon 24 of a 33 exon gene. It predicts the substitution of a conserved arginine to histidine at residue 1205 (p.Arg1205His) of the protein.
A cross-species alignment of the eIF4G1 demonstrated the p.Arg1205His is highly conserved across species ( Figure S1 ). In silico analysis predicts the mutation might be damaging to protein function (Polyphen-2 PSIC score ¼ 0.99).
Screening of EIF4G1 c.3614G>A (p.Arg1205His) in Individuals with PD To further investigate the pathogenicity of the EIF4G1 c.3614G>A (p.Arg1205His), we genotyped 4050 control subjects and 4708 individuals with idiopathic PD. We identified nine affected heterozygotes from seven families originating from the US (385-1493, 2498), Canada (2499), Ireland (32150-50), Italy (GE0925 and GE1843), and Tunisia (Tun83) ( Figure 1A) . A family history of parkinsonism was not evident in the Irish (32150-50), one Italian (GE0925), or the Tunisian (Tun83) subjects. In contrast, eIF4G1 p.Arg1205His was absent in control subjects.
To determine whether the EIF4G1 c.3614G>A (p.Arg1205His) mutation segregates with disease in these seven cases, we genotyped 42 STRs distributed across the 3q26-q28 locus flanking EIF4G1 c.3614G>A (Figure 2A ; Table S2A ). Haplotype analysis shows that each affected member of all seven families shares a minimal interval of 45,676bp (chr3:185,521,663-185,567,338) in common with family P30. With the exception of EIF4G1 c.3614G>A (p.Arg1205His) no other novel coding variant (Table S2 ). The maximum shared interval is 99,330 bp (MAX; chr3:185,519,706-185,619,035; gray and blue bars) and contains six gene transcripts, EIF4G1, FAM131A, CLCN2, POLR2H, THPO, and CHRD. The minimal shared interval is 45,676 bp (MIN; chr3:185,521,663-185,567,338; gray) and harbors four genes (EIF4G1, FAM131A, CLCN2, and POLR2H). EIF4G1 c.3614G>A (p.Arg1205His) is the only novel coding variant that segregates with disease. (B) The CEU haplotype map suggests negligible linkage disequilibrium across the rs4912537-D3S3578 region.
segregates with the disease in this shared haplotype, in which linkage disequilibrium between neighboring variants is marginal ( Figure 2B) . The results suggest the deleterious EIF4G1 c.3614G>A (p.Arg1205His) mutation originates from an ancestral founder and segregates with disease in seemingly unrelated families.
Screening for Novel EIF4G1 Variants in Other Families
To further evaluate the EIF4G1 mutations in PD, the 31 coding exons were sequenced in 95 randomly selected affected probands with autosomal-dominant parkinsonism, 130 pathologically-defined cases with Lewy body disease, and 185 ethnically matched controls. Sequence analysis identified eight novel coding variants in affected subjects (4 missense, 4 silent), three novel changes in controls (two missense, one silent), and three novel coding variants in affected and control subjects (Table S3 ). The four missense mutations not observed in controls were c.1505C>T (p.Ala502Val), c.2056G>T (p.Gly686Cys), c.3490A>C (p.Ser1164Arg), and c.3589C>T (p.Arg1197Trp) (Table S3) . They were detected in two affected probands with parkinsonism (US 623, US 385-1391) and two autopsied cases with Lewy body disease (US 331-5, US 331-95) ( Figure 1B ).
These four variants were subsequently genotyped in a case-control series consisting of 4483 individuals with idiopathic PD and 3865 age, gender, and ethnically matched control subjects. Screening identified only affected heterozygotes p.Ala502Val (US 385-284 and Poland 1736-155) and p.Gly686Cys (2 with PD in the family French P141), whereas the p.Ser1164Arg and p.Arg1197Trp mutations were not observed again in affected or control subjects.
Consistent with eIF4G1 p.Arg1205His, the p.Gly686Cys, p.Ser1164Arg, and p.Arg1197Trp mutations are also evolutionarily conserved in mammals ( Figure S1 ). Similarly, eIF4G1 p.Ala502Val is conserved in most mammals with the exception of the rabbit that has a valine at this position. Limited cross-species conservation typically argues against pathogenicity, but the first alpha-synuclein p.Ala53Thr mutation linked to PD is a notable precedent. 15 Assessment of segregation with disease was not possible for p.Ala502Val, p.Gly686Cys, p.Ser1164Arg, and p.Arg1197Trp mutations, and as a consequence genetic evidence for pathogenicity is limited. STR marker analysis of chromosomal region 3q26-q28 in all heterozygotes with p.Ala502Val suggested an ancestral founder, although the phase was only available for one pedigree (Table S2A) .
Clinical Findings and Neuropathological Analyses
Within family P30, the clinical phenotype among EIF4G1 c.3614G>A (p.Arg1205His) heterozygotes is consistent with late-onset PD, with a mean onset of 64 5 10.3 standard deviation (SD) years (n ¼ 10), but spans a broad range (50-80 years) ( Figure 1A ). Symptoms start insidiously with asymmetric resting tremor or akinetic rigidity and become progressively mixed. The parkinsonism has a relatively long, mild course, and cognition seems preserved. Patients' symptoms respond well to L-DOPA, but many remain untreated or use only dopamine agonists. In clinically symptomatic individuals' dopaminergic imaging with I-123 Ioflupan, DaTSCAN is abnormal and asymmetric. The clinical phenotype among unrelated subjects with a heterozygous EIF4G1 c.3614G>A (p.Arg1205His) mutation was comparable to family P30 with a mean symptom onset of 59 5 13.0 SD years (n ¼ 9), range 32-77 years ( Figure 1A) . Overall, affected subjects with an EIF4G1 c.1505C>T (p.Ala502Val) mutation have a mean age of symptom onset of 52 5 8.1 SD years (range 41-58 years, n ¼ 4) ( Figure 1B) .
The Figures 1B and 1D) . The Lewy body pathology in these cases is presented in Figure S2 .
Functional Analyses of eIF4G1 p.Arg1205His and p.Ala502Val Substitutions eIF4G1 p.Arg1205His is just distal to the putative eIF3e binding domain (amino acids 1015-1118; Figure S3 ), a key partner of the translation initiation complex that recruits the 40 S ribosomal subunit. [16] [17] [18] Thus, we evaluated WT and mutant eIF4G1 binding to eIF3e. Plasmids containing eIF4G1 WT or eIF4G1 p.Arg1205His or eIF4G1 LacZ were transfected into HEK293 cells. Coimmunoprecipitation studies of protein lysates from mutant eIF4G1-transfected cells show that p.Arg1205His perturbs eIF3e binding, but the WT protein does not ( Figure 3 ). eIF4G1 p.Ala502Val is the most frequent substitution encountered in other familial cases, although genetic evidence for segregation with disease and thus pathogenicity is limited. Its physical location predicts that the substitution might perturb eIF4E binding (amino acids 612-618). Coimmunoprecipitation studies of protein lysates from mutant eIF4G1 transfected cells show p.Ala502Val perturbs eIF4E binding compared to WT protein (Figure 3) . Both p.Ala502Val and p.Arg1205His are located within or proximal to the eIF4A-interacting domains (amino acids 761-988 and 1240-1450) but do not appear to affect its binding, although a nonsignificant trend toward increased binding was observed for p.Ala502Val.
When TMRE, a marker for mitochondrial membrane polarization, was applied to either WT or mutant (p.Ala502Val; p.Arg1205His) eIF4G1 transfected cells, no differences could be detected under basal conditions. 10 However, with hydroperoxide treatment, a profound loss in mitochondrial membrane potential was observed for both mutations but not for cells overexpressing WT protein (Figure 4) . Complementary results were obtained with patient-derived lymphoblastoid cell lines (data not shown). When starvation was used as an alternate stressor, the induction of autophagy was comparable in WT and mutant (p.Ala502Val; p.Arg1205His) overexpressing cells.
The lack of response might reflect the presence of endogenous eIF4G1 ( Figure S4 ). 9 Discussion eIF4G1 is the core scaffold of a multisubunit translation initiation complex that regulates the translation initiation of mRNAs encoding mitochondrial, cell survival and growth genes in response to different stresses. 9, 10 The pathogenicity of EIF4G1 mutations is supported by (1) the segregation of eIF4G1 p.Arg1205His with disease in a family with multi-incident autosomal-dominant, parkinsonism; (2) the absence of eIF4G1 p.Ala502Val and p.Arg1205His in control subjects (n ¼ 4050), although observed in several multi-incident families with autosomal-dominant late-onset PD; (3) an eIF4G1 p.Arg1205His haplotype suggestive of one ancestral founder, and delimiting the candidate gene interval; (4) the sequence conservation of eIF4G1p.Ala502Val and p.Arg1205His substitutions suggesting these mutations might be functionally deleterious; and (5) impaired binding of eIF4G1 p.Ala502Val and p.Arg1205His to eIF4E or eIF3e, interactions that are normally required for translation initiation. 17, 18 Both p.Ala502Val and p.Arg1205His directly impair formation of the larger eIF4 complex and support the genetic argument for a dominant-negative loss-offunction compatible with an age-dependent neurodegenerative disorder; (6) the loss of mitochondrial membrane potential and viability in transfected cells subjected to oxidative stress. The functional data presented are cursory and further analyses of mitochondrial biogenesis, autophagy, and transcription and translation, in additional models is warranted. A caveat of linkage within a multi-incident family is that there remains a remote possibility of a missing segregating variant, most likely within the diseasesegregating haplotype. Although rare, additional EIF4G1 mutations in other families will be important to discover. EIF4G1 mutations directly implicate mRNA translation initiation in parkinsonism and might help unify other monogenic forms, toxin, and perhaps virally-induced disease within a convergent pathway. 19, 20 Availability of eIF4E is generally the rate-limiting step of translation initiation and is largely determined by phosphorylation of eIF4E-binding proteins (4E-BP) through the mammalian target of the rapamycin (mTOR) pathway. 9, 21 Constitutive activity of mTOR signaling normally leads to phosphorylation of 4E-BPs; this dislodges eIF4E and enables assembly of the eIF4F complex to promote cap-dependent translation ( Figure S3 ). 18 Notably, 4E-BP is a substrate of human Lrrk2 and the Drosophila ortholog (Lrrk). The variability in clinical and pathologic presentation of affected members of EIF4G1 families is similar to genetically-defined parkinsonism but most consistent with idiopathic, late-onset Lewy body PD. Although EIF4G1 mutations represent a molecular mechanism for PD, genetic defects in translation have been implicated in many neurological diseases. 24 Most are private mutations in orphan families. Nevertheless, the three-fold increase in rare EIF4G1 coding variants in PD compared to control subjects warrants further study. Common polymorphic variability in the EIF4G1 locus was not associated with PD in case-control samples. These data suggest that eIF4G1 p.Ala502Val and p.Arg1205His substitutions affect scaffold function and consequently impair the ability of cells to rapidly and dynamically respond to stress, presumably through changes in the translation of existing mRNAs essential to cell survival. 9, 10 Perturbations in mTOR/4E-BP signaling and eIF4G1-mediated changes in mRNA translation will be important to elucidate in neurons in vivo. The pathway highlighted might represent a central theme in PD for which targeted interventions already have therapeutic potential. 
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